已收盤 11-20 16:00:00 美东时间
-0.980
-4.32%
今日重点评级关注:花旗:维持Faeth Therapeutics"买入"评级,目标价从55美元升至60美元;HC Wainwright & Co.:维持Ocular Therapeutix"买入"评级,目标价从25美元升至28美元
11-11 10:50
Wedbush analyst Robert Driscoll maintains Tango Therapeutics (NASDAQ:TNGX) with a Outperform and lowers the price target from $45 to $40.
11-10 23:33
Tango Therapeutics (NASDAQ:TNGX) reported quarterly losses of $(0.39) per share which missed the analyst consensus estimate of $(0.35) by 11.43 percent. This is a 378.57 percent decrease over earnings of $0.14 per share from the same period last year.
11-09 20:36
Tango Therapeutics and Erasca have launched a Phase 1/2 trial combining vopimetostat, a PRMT5 inhibitor, with ERAS-0015, a pan-RAS molecular glue, to treat MTAP-deleted pancreatic cancer and MTAP-deleted/RAS-mutant non-small cell lung cancer. The study aims to assess safety, tolerability, and antitumor activity of this combination. Both companies believe targeting PRMT5 and RAS together could offer a promising approach for these cancers.
11-04 13:30
Tango Therapeutics, Inc. announced that its CEO, Malte Peters, M.D., will participate in a fireside chat at Guggenheim’s 3rd Annual Healthcare Innovation Conference on November 10, 2026, at 8:00 AM EST. The live webcast will be available on the Company’s website under the "Events & Presentations" tab, with a replay archived for 90 days. Tango Therapeutics is a clinical-stage biotech company focused on developing targeted therapies for cancer pati...
11-03 12:00
进入年底,医药行业裁员消息密集释放。从跨国药企的全球降本计划,到 Biotech 因临床、商业化不及预期被动缩编,一起来看看本月行业裁员事件汇总。 10 月 ...
10-30 17:06
今日重点评级关注:Canaccord Genuity:维持Wave Life Sciences"买入"评级,目标价从42美元升至44美元;Canaccord Genuity:维持Pharming Group"买入"评级,目标价从38美元升至41美元
10-30 12:30
在今年的美国临床肿瘤学会(ASCO)年会上,Revolution Medicines开发的RAS抑制剂daraxonrasib凭借3期临床试验的积极结果,赢得全...
10-26 18:01
Tango Therapeutics shares are trading lower after the company announced results from its Phase 1/2 study of vopimetostat. A median PFS was not reached.
10-23 20:40
Tango Therapeutics, Inc. (NASDAQ:TNGX), a clinical-stage biotechnology company committed to discovering and delivering the next generation of precision cancer medicines, today announced that the Company will present updated data from a Phase 1/2 study of vopimetostat in combination with daraxonrasib...
10-16 19:05